MITA APPLAUDS INTRODUCTION OF H.R. 6948, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018


Legislation, introduced by Congressmen George Holding (NC-2) and Seth Moulton (MA-6) ensures equitable payment for and preserves Medicare beneficiary access to diagnostic radiopharmaceuticalswhile granting consideration of innovative diagnostics in Medicare hospital outpatient setting

WASHINGTON – The Medical Imaging & Technology Alliance (MITA) – the leading organization and collective voice of medical imaging equipment, radiopharmaceutical manufacturers, innovators, and product developers – applauds Congressmen Holding and Moulton for introducing legislation that recognizes diagnostic radiopharmaceuticals as drugs in the Medicare Hospital Outpatient Prospective Payment System.

The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 would allow patients appropriate access to much needed diagnostic radiopharmaceuticals for a multitude of diseases, which include cancer, neurologic, and cardiac conditions.”

Diagnostic radiopharmaceuticals assist physicians as they diagnose and determine the severity of potentially life-threateningdiseases.  These procedures improve diagnostic accuracy, which in turn help physicians develop treatment strategies to avoid potentially unnecessary procedures for multiple cancers such as prostate, lymphoma, colon, breast, melanoma, andlung.  Radiopharmaceuticals also assist in the diagnosis of cardiac conditions and degenerative neurological diseases such as Parkinson’s and Alzheimer’s diseases.

According to Bill Abbott of Life Molecular Imaging, and Chair of the MITA PET Group, “This legislation will allow essential radiopharmaceuticals to be accurately consideredas drugs and paid separately in the Medicare hospital outpatient setting.  Passage of this legislation will remove the disincentive to innovation and contribute to greater patient access to these important diagnostic tests.”